Pathophysiology and Management of Diabetic Gastroenteropathy

Total Page:16

File Type:pdf, Size:1020Kb

Load more

university of copenhagen

Pathophysiology and management of diabetic gastroenteropathy

Meldgaard, Theresa; Keller, Jutta; Olesen, Anne Estrup; Olesen, Søren Schou; Krogh, Klaus; Borre, Mette; Farmer, Adam; Brock, Birgitte; Brock, Christina; Drewes, Asbjørn Mohr

Published in:

Therapeutic Advances in Gastroenterology

DOI:

10.1177/1756284819852047

Publication date:

2019

Document version

Publisher's PDF, also known as Version of record

Document license:

CC BY-NC

Citation for published version (APA):

Meldgaard, T., Keller, J., Olesen, A. E., Olesen, S. S., Krogh, K., Borre, M., Farmer, A., Brock, B., Brock, C., & Drewes, A. M. (2019). Pathophysiology and management of diabetic gastroenteropathy. Therapeutic Advances in Gastroenterology, 12, 1-17. https://doi.org/10.1177/1756284819852047

Download date: 01. Oct. 2021

852047

  • TAG0010.1177/1756284819852047Therapeutic Advances in GastroenterologyT Meldgaard, Keller
  • J

review-article20192019

Therapeutic Advances in Gastroenterology

Review

Ther Adv Gastroenterol

Pathophysiology and management of diabetic gastroenteropathy

2019, Vol. 12: 1–17

hDttOpsI:://d1o0i.o.r1g1/170.711/77/1756284819852047

https://doi.org/10.1177/1756284819852047

1756284819852047 © The Author(s), 2019. Article reuse guidelines: sagepub.com/journals- permissions

Theresa Meldgaard, Jutta Keller, Anne Estrup Olesen, Søren Schou Olesen, Klaus Krogh, Mette Borre, Adam Farmer, Birgitte Brock, Christina Brock and Asbjørn Mohr Drewes

Correspondence to:

Theresa Meldgaard

Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Denmark

Abstract: Polyneuropathy is a common complication to diabetes. Neuropathies within the enteric nervous system are associated with gastroenteropathy and marked symptoms that severely reduce quality of life. Symptoms are pleomorphic but include nausea, vomiting, dysphagia, dyspepsia, pain, bloating, diarrhoea, constipation and faecal incontinence. The aims of this review are fourfold. First, to provide a summary of the pathophysiology underlying diabetic gastroenteropathy. Secondly to give an overview of the diagnostic methods. Thirdly, to provide clinicians with a focussed overview of current and future methods for pharmacological and nonpharmacological treatment modalities. Pharmacological management is categorised according to symptoms arising from the upper or lower gut as well as sensory dysfunctions. Dietary management is central to improvement of symptoms and is discussed in detail, and neuromodulatory treatment modalities and other emerging management strategies for diabetic gastroenteropathy are discussed. Finally, we propose a diagnostic/investigation algorithm that can be used to support multidisciplinary management.

Department of Clinical Medicine, Aalborg University, Denmark

[email protected]

Jutta Keller

Israelitic Hospital in Hamburg, Academic Hospital University of Hamburg, Germany

Anne Estrup Olesen

Mech-Sense, Department of Gastroenterology and Hepatology and Department of Clinical Medicine, Aalborg University Hospital, Denmark

Keywords: diabetes mellitus, complications, diabetic neuropathies, enteric nervous system, gastrointestinal motility, gastrointestinal transit, pharmacology, enteropathy

Department of Clinical Medicine, Aalborg University, Denmark
Received: 5 February 2019; revised manuscript accepted: 26 April 2019.

Søren Schou Olesen

Mech-Sense, Department of Gastroenterology and Hepatology and Department of Clinical Medicine, Aalborg University Hospital, Denmark

Introduction

Although often overlooked, effects in the auto-
The development of diabetic polyneuropathy can nomic nervous system most likely occur concurpotentially alter neuronal structure and function rently with those observed in the somatic nervous anywhere in the peripheral, central and enteric system. For example it is plausible that early damnervous systems. Where small and large fibres age to small fibres, preceding large fibre neuropa(unmyelinated C and myelinated Aβ and Aδ fibres) thy, of the somatic nerves, which can be observed in the somatic sensory nervous system are affected, in skin biopsies4 also take place in other small fibres the typical manifestation is a distal symmetrical such as in the enteric nervous system. Autonomic polyneuropathy.1 Importantly, these symptoms neuropathy can be clinically silent and is often precan also be found in people with prediabetes.2 The sent when polyneuropathy of the somatic nerves is somatic polyneuropathy is characterised by altera- present. The diagnosis is typically based on cardiotions in the sensory system, and classically presents vascular abnormalities. In particular, studies of with marked changes in a number of sensations RR-complexes in electrocardiograms have been (including temperature and fine touch, balance, used to describe heart rate variability, leading to etc.) and can be painful or painless, although the the diagnosis of cardiac autonomic neuropathy. former predominates.2 In community samples However, autonomic neuropathy also leads to gaswith diabetes, the prevalence of clinical symptoms trointestinal (GI) complications such as diabetic is in the order of 30%, although this is likely to gastroenteropathy, which may affect the entire represent an underestimate as many people are not length of the GI tract. The underlying pathophysi-

Department of Clinical Medicine, Aalborg University, Denmark

Christina Brock

Mech-Sense, Department of Gastroenterology and Hepatology and Department of Clinical Medicine, Aalborg University Hospital, Denmark Department of Clinical Medicine, Aalborg University, Denmark

Asbjørn Mohr Drewes

Mech-Sense, Department of Gastroenterology and Hepatology and Department of Clinical Medicine, Aalborg University Hospital, Denmark Department of Clinical Medicine, Aalborg University, Denmark

  • formally diagnosed.3
  • ology, which is driven by a multitude of factors,

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Therapeutic Advances in Gastroenterology 12

Klaus Krogh

including microenvironmental factors such as cues from interstitial cells of Cajal (which are also

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark

hyperglycaemia, have a negative impact on the reduced in number).9 This link between reduced enteric motor and sensory functions and manifest numbers of interstitial cells of Cajal and smooth as symptoms related to, e.g., motility and secretory muscle myopathy has been observed in animal dysfunctions.5–7 Hence, people with diabetic gas- models of diabetic gastroparesis and likely controenteropathy may experience a variety of bur- tributes to abnormal motility.

Mette Borre

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark

densome symptoms, including dysphagia, dyspepsia, pain, bloating, diarrhoea, constipation The autonomic nervous system comprises (a) and faecal incontinence, all of which adversely the sympathetic nervous system, (b) the para-

Adam Farmer

Department of Gastroenterology, University Hospitals of North Midlands, Stoke on Trent, Staffordshire, UK

  • influences quality of life.
  • sympathetic nervous system (whose main neural

substrate is the vagus nerve) and, according to
Although the focus of this review is diabetic gas- the early and recently re-established definition, troenteropathy, it should be emphasized that (c) the enteric nervous system.10,11 Alterations in functional GI disorders are prevalent in the com- either of these systems are involved in the undermunity. Hence, the presentation of diabetic gas- lying mechanism of burdensome GI complicatroenteropathy and functional disorders such as tions in diabetes. As both the enteric nervous functional dyspepsia and irritable bowel syn- system and central nervous system (CNS) are drome overlap and cannot be distinguished on involved in the bidirectional regulation and conthe basis of symptoms or medical history (i.e. trol of the GI homeostasis, any changes in either diabetes) alone. In fact, examinations of small of these interconnected systems may result in bowel biopsies from patients with diabetes altered GI function.

Centre for Digestive Diseases, Blizard Institute of Cell and Molecular Science, Wingate Institute of Neurogastroenterology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK

Birgitte Brock

Department of Clinical Research, Steno Diabetes Center Copenhagen (SDCC), Denmark

revealed neuropathy and myopathy only in a minority of patients.8 It is also clear that individuals with chronic disease have a higher preva- Changes at the level of the enteric nervous lence of psychiatric disorders and are exposed to system more stress than healthy subjects. These factors In diabetes, the microenvironment within the play an important role in the presentation and enteric nervous system is significantly altered due

  • perceived severity of functional GI diseases.
  • to the effect of e.g. long-term hyperglycaemia; oxi-

dative stress; inflammation; reduced levels of neuro
The aims of this review are, however, to describe transmitters, local hormones and nerve growth facthe pathophysiology of GI complications to dia- tors; and increased levels of fatty acids.12,13 betic neuropathy (gastroenteropathy) and to out- Recently, altered gut luminal microbiota has also line diagnostics and recent pharmacological and been proposed to exert an influence. For example, nonpharmacological treatment modalities for this lowered numbers of bacteria involved in produc-

  • burdensome condition.
  • tion of short chain fatty acids have been observed

in diabetes. Short chain fatty acids have antiinflammatory effects in the GI wall and promote the secretion of the incretin hormone glucagonlike peptide-1 (GLP-1). Lower levels of GLP-1

Pathophysiology of diabetes-induced gastrointestinal complications

The term diabetic gastroenteropathy encom- influence glucose metabolism and can increase passes the cumulative impact that diabetes exerts low-grade inflammation.14–18 on the GI tract. The pathophysiology is multifactorial and to date remains incompletely under- Various components of the enteric nervous sysstood. However, changes in the neuronal tem, (including enteric neurons, interstitial cells of microenvironment are believed to be a major Cajal, enteric glial cells) and smooth muscle cells driver in the pathogenesis. Microvascular compli- are affected by the changes described above. cations to diabetes lead to alterations of blood Enteric neurons and interstitial cells of Cajal are flow in the GI wall, and hence also to alterations particularly vulnerable to hyperglycaemia.19 When in the microenvironment. Smooth muscle myo- hyperglycaemic episodes are frequent, or when pathy is also thought to be a contributing factor to hyperglycaemia is persistent, shifts in the intraceldiabetic gastroenteropathy. However, smooth lular glucose metabolism of neurons occur, consemuscle myopathy may not be a primary distur- quently leading to the formation of advanced bance, but is more likely a result of smooth mus- glycation end-products, osmotic and oxidative cle cell atrophy induced through reduced trophic stress as well as inflammation. Collectively, this

T Meldgaard, J Keller et al.

leads to cellular damage and ultimately to cell been investigated in detail in healthy subjects, death, a process often referred to as glucose neu- but similar mechanisms are likely involved in rotoxicity. These mechanisms are primarily diabetes.31 described in the peripheral nervous system, but similar mechanisms are present in the enteric nervous system.20

Changes at the level of the autonomic nervous system

The pathophysiological changes described above Autonomic afferent and efferent signalling may lead to various degrees of diabetes-induced through the vagus nerve is directly involved in damage to enteric neurones. Preferential loss of the extensive communication with the brain, large fibre neurons in the dorsal root ganglion forming the so-called gut-brain-axis. In both and inhibitory motor neurons in the gut wall people with diabetes and in animal models, the have been observed. In particular, selective loss number of neurons in the sympathetic and paraof nitric oxide synthase and neuropeptideY sympathetic ganglions of the vagus nerve conexpressing inhibitory motor neurons has been nected to the GI tract is reduced32–34 as well as shown in the human diabetic colon.21 This obvi- structural changes in the axons have been ously has consequences for the contractile activ- reported.35,36 In consequence, autonomic neuity of the smooth muscle layers in the GI tract ropathy, influencing the vagus nerve, contributes and hence the motility pattern. Furthermore, loss to reduced GI function. of interstitial cells of Cajal throughout the GI tract has been reported in both animal models and in humans,22,23 causing reduced frequency of Changes at the level of the CNS spontaneous muscular contractions. In addition, Although the blood–brain barrier offers some decreased activity of gastric enteric glial cells has protection to the brain against hyperglycaemia, it been observed in animal models of diabetes.24 has been observed that the microstructure in speThis may contribute to the development of gas- cific brain regions (diabetic encephalopathy) troenteropathy in diabetes mainly because enteric involved in visceral sensory processing is changed glial cell functions such as neurotrophic support, in diabetes.37 immunosuppression and anti-inflammation is

  • diminished with decreased activity.25,26
  • Manifestation of sensory symptoms from the

abdomen, such as nausea, vomiting and pain, as
In contrast to the loss of motor neurons, it has well as unspecific fullness, shooting sensations, recently been shown that levels of neurones con- etc., may relate to abnormal function of the sentaining substanceP and calcitonin gene-related sory visceral nerves in combination with the peptide are increased in the stomach of porcine encephalopathy (Figure 1). models of diabetes.27 Both these molecules are primarily involved in the afferent transmission of We have previously shown that central reorganiGI sensory and nociceptive information. Hence, sation of brain responses to visceral stimuli is such alterations may be related to the pathophys- associated to the burden of GI symptoms as well iological mechanisms of sensory symptom gen- as heart rate variability as a proxy for diabetic eration. Like in the somatic system, when sensory autonomic neuropathy.38,39 This was supported nerves are affected by enteropathy, pain from the by another study where visceral hyposensitivity gut can likely be spontaneous or evoked by exter- was correlated to an increase in somatic referred nal or internal stimuli such as disturbances in pain areas, indicating central neuropathic-like motility and glandular functions. On the other changes.28 Although controversies exist regarding hand, previous experimental studies where the the pathogenesis of these changes, the findings in gut was stimulated with electrical, mechanical the CNS may be secondary to the peripheral neuand thermal stimuli, hypoalgesia to peripheral ropathy, because the reduced afferent activity stimulation of both the upper and lower gut were may cause adaptive shrinking.37,40 Finally, there is shown, likely reflecting abnormal central pro- evidence from both neurophysiological and imagcessing of the afferent activity.28 Moreover, rectal ing studies that descending pathways from the pain thresholds are correlated to cutaneous and brainstem that normally ‘gates’ the incoming autonomic dysfunction.29,30 The autonomic nociceptive barrage is malfunctioning in people components of visceral hyperalgesia have only with diabetes.30,41 Hence, as in somatic peripheral

Therapeutic Advances in Gastroenterology 12

Diagnosis

As outlined above, diabetic gastroenteropathy can affect the entire GI tract, and consequently symptoms are not only very heterogeneous, they are also unspecific. The cardinal symptoms are nausea, vomiting, bloating and early satiety, however, symptoms range from dysphagia and heartburn to faecal incontinence. Thus, based on the patient reported symptoms, it is hardly possible to distinguish sequela of diabetes-associated GI dysfunction from organic diseases. This diagnostic dilemma is further aggravated by the fact that people with type2 diabetes have an increased risk for a multitude of organic GI diseases, including reflux oesophagitis, gallstones and GI malignancies.46 An increased cancer risk has also been observed in type1 diabetes.47 Moreover, increased prevalence of other diseases with an autoimmune component affecting the GI tract such as coeliac disease48 are frequent and need to be taken into consideration.

Figure 1. Neural pathways and mechanisms that

may lead to pain and other sensory symptoms from the gastrointestinal system in people with diabetic neuropathy.

Accordingly, it is important to first exclude organic disease using appropriate laboratory tests, endoscopy and imaging techniques in people presenting with symptoms that could be attributed to diabetic gastroenteropathy (Figure 2). If these tests are unrevealing and symptoms do not respond to simple therapeutic measures (e.g. laxatives in chronic constipation), GI function tests can be used to diagnose disturbances associated with diabetic gastroenteropathy. Again, most clinically available function tests identify and quantify dysfunction of various GI segments and organs without being able to specifically prove the causation by or the relative importance of diabetic

Neuropathic changes in the enteric nervous system where e.g., motility dysfunction can lead to sensory symptoms: (1) autonomic neuropathy influencing the parasympathetic (2) and (3) sympathetic pathways. Due to cross-talk between the nerve pathways and involvement of inhibitory pathways, this may indirectly modulate sensations from the gut; negative impact on visceral (4) (and somatic (5) if the peritoneum is involved) afferents lead to spontaneous and evoked pain. Structural and functional changes in the spinal cord (6) and brain (7) may lead to spontaneous and evoked pain, amplify afferent barrage and give abnormal referred pain to somatic structures (8). Spino-bulbo-spinal loops (9) that normally control pain intensity often malfunction in people with diabetes.

neuropathy, abnormal central sensory processing gastroenteropathy. For instance, severe oesophaand hyper-excitability may explain the visceral geal hypomotility diagnosed by high resolution symptoms despite the peripheral hypoalgesia (as manometry can explain nonobstructive dysphagia described above).42 Such neuroplastic mecha- in a person with diabetes, but could also be due to nisms were also seen e.g. in people with chronic other aetiologies. Therefore, clinical plausibility pancreatitis, which is thought to have a strong and affection of other organ systems, e.g. cardiac neuropathic component, and this validated the autonomic neuropathy, should be taken into

  • findings.43
  • account. Impaired pancreatic polypeptide release

has been suggested for specific diagnosis of gas-
In summary, long-term diabetes induces marked troenteropathy,49 but measurements are not structural and functional changes of the GI wall, widely available. Likewise, antroduodenojenunal parasympathetic, sympathetic and CNS altera- manometry with increased frequency of phase tions. Especially, intrinsic and extrinsic neuronal III-motility and hypomotility during phase II as communication of the GI tract is altered. Taken well as postprandially is typical of autonomic neutogether, this leads to burdensome panenteric ropathy, but available only at highly specialized alteration of GI sensation and function, includ- centres and reserved for people with very severe ing the biomechanics that drive GI motility.44,45 symptoms.50

Recommended publications
  • Fluoroscopic Characterization of Colonic Dysmotility Associated to Opioid and Cannabinoid Agonists in Conscious Rats

    Fluoroscopic Characterization of Colonic Dysmotility Associated to Opioid and Cannabinoid Agonists in Conscious Rats

    J Neurogastroenterol Motil, Vol. 25 No. 2 April, 2019 pISSN: 2093-0879 eISSN: 2093-0887 https://doi.org/10.5056/jnm18202 JNM Journal of Neurogastroenterology and Motility Original Article Fluoroscopic Characterization of Colonic Dysmotility Associated to Opioid and Cannabinoid Agonists in Conscious Rats Susana Díaz-Ruano,1 Ana E López-Pérez,1,5 Rocío Girón,2,3,4,5 Irene Pérez-García,2 María I Martín-Fontelles,2,3,4,5 and Raquel Abalo2,3,4,5* 1Unidad de Dolor, Servicio de Anestesiología, Hospital General Universitario Gregorio Marañón, Madrid, Spain; 2Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain; 3Unidad Asociada I+D+i al Instituto de Investigación en Ciencias de la Alimentación, CIAL (CSIC), Madrid, Spain; 4Unidad Asociada I+D+i al Instituto de Química Médica, IQM (CSIC), Madrid, Spain; and 5Grupo de Excelencia Investigadora URJC-Banco de Santander-Grupo Multidisciplinar de Investigación y Tratamiento del Dolor (i+DOL), Madrid, Spain Background/Aims Gastrointestinal adverse effects have a major impact on health and quality of life in analgesics users. Non-invasive methods to study gastrointestinal motility are of high interest. Fluoroscopy has been previously used to study gastrointestinal motility in small experimental animals, but they were generally anesthetized and anesthesia itself may alter motility. In this study, our aim is to determine, in conscious rats, the effect of increasing doses of 2 opioid (morphine and loperamide) and 1 cannabinoid (WIN 55,212-2) agonists on colonic motility using fluoroscopic recordings and spatio-temporal maps. Methods Male Wistar rats received barium sulfate intragastrically, 20-22 hours before fluoroscopy, so that stained fecal pellets could be seen at the time of recording.
  • Akt Phosphorylation of Neuronal Nitric Oxide Synthase Regulates Gastrointestinal Motility in Mouse Ileum

    Akt Phosphorylation of Neuronal Nitric Oxide Synthase Regulates Gastrointestinal Motility in Mouse Ileum

    Akt phosphorylation of neuronal nitric oxide synthase regulates gastrointestinal motility in mouse ileum Damian D. Guerraa, Rachael Boka, Vibhuti Vyasa, David J. Orlickyb, Ramón A. Lorcaa, and K. Joseph Hurta,c,1 aDivision of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045; bDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045; and cDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045 Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved July 15, 2019 (received for review April 5, 2019) Nitric oxide (NO) is a major inhibitory neurotransmitter that mediates receptor activation (18–20). Some evidence suggests that phosphor- nonadrenergic noncholinergic (NANC) signaling. Neuronal NO syn- ylation of the equivalent Akt/PKA consensus site in nNOS, ser- + thase (nNOS) is activated by Ca2 /calmodulin to produce NO, which ine1412 (S1412), also stimulates neuronal NO synthesis (21). Because + causes smooth muscle relaxation to regulate physiologic tone. nNOS nNOS activity is more sensitive to [Ca2 ](21),andnNOSismore serine1412 (S1412) phosphorylation may reduce the activating rapidly dephosphorylated than eNOS (22), it is technically difficult to 2+ Ca requirement and sustain NO production. We developed and evaluate nNOS S1412 phosphorylation in vivo. Nonetheless, studies S1412A characterized a nonphosphorylatable nNOS knock-in mouse implicate nNOS S1412 phosphorylation in hippocampal excitotoxicity and evaluated its enteric neurotransmission and gastrointestinal (4), penile erection (22), and luteinizing hormone release (23). (GI) motility to understand the physiologic significance of nNOS Enteric neurons express high levels of nNOS, Akt, and PKA S1412 phosphorylation.
  • Gastrointestinal Motility Disorders

    Gastrointestinal Motility Disorders

    Gastrointestinal Motility Disorders Jassin M. Jouria, MD Dr. Jassin M. Jouria is a medical doctor, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serve as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. Abstract The muscles of the gastrointestinal (GI) tract perform an important job. The GI tract peristalsis, or contractions, mix the contents of the stomach and propel contents throughout the entire GI tract until they exit as waste. When these muscles underperform or fail to perform, it can create serious and painful consequences, diagnosed as GI motility disorders. Although these disorders are rarely fatal, they can cause physical and emotional effects that negatively impact a patient's quality of life.
  • The Plasmapheresis in the Treatment of Guillain-Barré Syndrome

    The Plasmapheresis in the Treatment of Guillain-Barré Syndrome

    Merit Research Journal of Medicine and Medical Sciences (ISSN: 2354-323X) Vol. 7(2) pp. 066-072, February, 2019 Available online http ://www.meritresearchjournals.org/mms/index.htm Copyright © 2019 Merit Research Journals Case Report The Plasmapheresis in the Treatment of Guillain-Barre ́ Syndrome Associated with Primary Enteric Neuropathy, Case Report. Up-Date Data from Literature Lungu Mihaela 1* and Sapira Violeta 2 Abstract 1Assoc. Prof., Head of Neurological The article presents a case with a particular clinical situation that has Department, Emergency Clinical associated an enteric neuropathy with an evolution of over two months, with Hospital Galati, Romania; Faculty of a Guillain-Barré syndrome (Landry type), both remitted after Medicine and Pharmacy, “Dunarea de plasmapheresis. A 53 year old male patient has been admitted in our Jos” University of Galati, Romania Neurological Department with dehydration, syncope and orthostatic 2Assist. Prof., Neurological hypotention, due to an enteric neuropathie, complicated in 8 days with a Department, Emergency Clinical Guillain Barré syndrome-GBS. This type of associated diseases is rarely Hospital Galati, Romania; Faculty of described in the literature, being well known that GBS can be precede with Medicine and Pharmacy, “Dunarea de two weeks in advance by a diarrheic episode. In our case, a chronic Jos” University of Galati, Romania diarrheic sufferance was involved- an enteric neuropathy. Both types of neurological manifestations had an obvious improvement after *Corresponding Author’s
  • Chronic Intestinal Pseudo-Obstruction As an Expression Of

    Chronic Intestinal Pseudo-Obstruction As an Expression Of

    GE Port J Gastroenterol. 2014;21(6):254---257 www.elsevier.pt/ge CLINICAL CASE Chronic intestinal pseudo-obstruction as an expression of inflammatory enteric neuropathy a,∗ a a b a Rita Pimentel , Marta Salgado , Maria João Magalhães , Ana Accarino , Isabel Pedroto a Gastroenterology Department, Centro Hospitalar do Porto, Hospital de Santo António, Porto, Portugal b Gastroenterology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain Received 22 December 2013; accepted 28 July 2014 Available online 22 November 2014 KEYWORDS Abstract Chronic intestinal pseudo-obstruction (CIPO) is characterised by inadequate diges- tive tract motility and can lead to severely disordered motility. CIPO manifests as recurrent Chronic intestinal pseudo-obstruction; episodes of intestinal sub-occlusion without an anatomical obstruction. We present the case Neuropathy; of a 41-year-old female, with severe chronic constipation and several episodes of intesti- Bowel nal sub-occlusion. Investigation revealed colonic inertia and marked distension of the small bowel and colon with no evidence of stenosis or obstructive lesions, compatible with CIPO. After several treatments were tried (domperidone, erythromycin, cisapride, octreotide, total enteral nutrition), with partial or no response, further work-up was done trying to identify an etiology. Gastrointestinal manometry showed neuropathic type abnormalities, transmural biopsy of the jejunum revealed degenerative enteric neuropathy and anti-HU antineuronal antibody screen was positive, suggesting an autoimmune type neuropathy with diffuse involve- ment of the digestive tract. Corticosteroids showed partial improvement of short duration and azathioprine was also tried but discontinued due to intolerance. Marked dietary intolerance and malnutrition lead to total parenteral nutrition (TPN) at home since October 2011.
  • Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons

    Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons

    ORIGINAL RESEARCH published: 08 June 2017 doi: 10.3389/fphys.2017.00391 Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons Rachel M. McQuade 1, Vanesa Stojanovska 1, Elizabeth L. Donald 1, Ahmed A. Rahman 1, Dean G. Campelj 1, 2, 3, Raquel Abalo 4, Emma Rybalka 1, 2, 3, Joel C. Bornstein 5 and Kulmira Nurgali 1* 1 College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia, 2 Institute of Sport, Exercise and Active Living, Victoria University, Melbourne, VIC, Australia, 3 Australian Institute of Musculoskeletal Science, Western Health, Edited by: Melbourne, VIC, Australia, 4 Área de Farmacología y Nutrición y Unidad Asociada al Instituto de Química Médica y al Instituto L. Ashley Blackshaw, de Investigación en Ciencias de la Alimentación del Consejo Superior de Investigaciones Científicas, Grupo de Excelencia Queen Mary University of London, Investigadora URJC-Banco de Santander-Grupo Multidisciplinar de Investigación y Tratamiento del Dolor, Universidad Rey United Kingdom Juan Carlos, Alcorcón, Spain, 5 Department of Physiology, Melbourne University, Melbourne, VIC, Australia Reviewed by: Patrick Anthony Hughes, Gastrointestinal dysfunction is a common side-effect of chemotherapy leading to dose University of Adelaide, Australia Rainer Viktor Haberberger, reductions and treatment delays. These side-effects may persist up to 10 years Flinders University, Australia post-treatment. A topoisomerase I inhibitor, irinotecan (IRI), commonly used for the *Correspondence: treatment of colorectal cancer, is associated with severe acute and delayed-onset Kulmira Nurgali [email protected] diarrhea. The long-term effects of IRI may be due to damage to enteric neurons innervating the gastrointestinal tract and controlling its functions.
  • Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives

    Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives

    Journal of Clinical Medicine Review Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives Ditte S. Kornum 1,2,* , Astrid J. Terkelsen 3, Davide Bertoli 4, Mette W. Klinge 1, Katrine L. Høyer 1,2, Huda H. A. Kufaishi 5, Per Borghammer 6, Asbjørn M. Drewes 4,7, Christina Brock 4,7 and Klaus Krogh 1,2 1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, DK8200 Aarhus, Denmark; [email protected] (M.W.K.); [email protected] (K.L.H.); [email protected] (K.K.) 2 Steno Diabetes Centre Aarhus, Aarhus University Hospital, DK8200 Aarhus, Denmark 3 Department of Neurology, Aarhus University Hospital, DK8200 Aarhus, Denmark; [email protected] 4 Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, DK9100 Aalborg, Denmark; [email protected] (D.B.); [email protected] (A.M.D.); [email protected] (C.B.) 5 Steno Diabetes Centre Copenhagen, Gentofte Hospital, DK2820 Gentofte, Denmark; [email protected] 6 Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, DK8200 Aarhus, Denmark; [email protected] 7 Steno Diabetes Centre North Jutland, Aalborg University Hospital, DK9100 Aalborg, Denmark * Correspondence: [email protected] Abstract: The autonomic nervous system delicately regulates the function of several target organs, including the gastrointestinal tract. Thus, nerve lesions or other nerve pathologies may cause autonomic dysfunction (AD). Some of the most common causes of AD are diabetes mellitus and α-synucleinopathies such as Parkinson’s disease. Widespread dysmotility throughout the gastroin- Citation: Kornum, D.S.; Terkelsen, testinal tract is a common finding in AD, but no commercially available method exists for direct A.J.; Bertoli, D.; Klinge, M.W.; Høyer, K.L.; Kufaishi, H.H.A.; Borghammer, verification of enteric dysfunction.
  • Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems

    Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems

    International Journal of Molecular Sciences Review Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems Weixia Zhong 1, Omar Shahbaz 2, Garrett Teskey 1, Abrianna Beever 3, Nala Kachour 3, Vishwanath Venketaraman 1,3 and Nissar A. Darmani 1,* 1 Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, 309 East Second Street, Pomona, CA 91766, USA; [email protected] (W.Z.); [email protected] (G.T.); [email protected] (V.V.) 2 School of Medicine, Universidad Iberoamericana, Av. Francia 129, Santo Domingo 10203, Dominican Republic; [email protected] 3 Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA 91766, USA; [email protected] (A.B.); [email protected] (N.K.) * Correspondence: [email protected]; Tel.: +1-909-469-5654 Abstract: Nausea and vomiting are common gastrointestinal complaints that can be triggered by diverse emetic stimuli through central and/or peripheral nervous systems. Both nausea and vomiting are considered as defense mechanisms when threatening toxins/drugs/bacteria/viruses/fungi enter the body either via the enteral (e.g., the gastrointestinal tract) or parenteral routes, including the blood, skin, and respiratory systems. While vomiting is the act of forceful removal of gastrointestinal contents, nausea is believed to be a subjective sensation that is more difficult to study in nonhuman species. In this review, the authors discuss the anatomical structures, neurotransmitters/mediators, Citation: Zhong, W.; Shahbaz, O.; and corresponding receptors, as well as intracellular emetic signaling pathways involved in the Teskey, G.; Beever, A.; Kachour, N.; processes of nausea and vomiting in diverse animal models as well as humans.
  • Pediatric Enteric Neuropathies: Diagnosis and Current Management

    Pediatric Enteric Neuropathies: Diagnosis and Current Management

    CE: Swati; COPE-D-17-00007; Total nos of Pages: 7; COPE-D-17-00007 REVIEW CURRENT OPINION Pediatric enteric neuropathies: diagnosis and current management Maggie L. Westfala and Allan M. Goldsteinb,c Purpose of review Neurointestinal diseases are increasingly recognized as causes of significant gastrointestinal morbidity in children. This review highlights the most common pediatric enteric neuropathies and their diagnosis and management, emphasizing insights and discoveries from the most recent literature available. Recent findings The embryologic and histopathologic causes of enteric neuropathies are varied. They range from congenital aganglionosis in Hirschsprung disease, to autoimmune-mediated loss of neuronal subtypes in esophageal achalasia and Chagas disease, to degenerative neuropathies in some cases of chronic intestinal pseudo-obstruction and gastroparesis. Increased awareness of the clinical presentation and diagnostic evaluation of these conditions is essential as it allows for earlier initiation of treatment and improved outcomes. Most current therapies, which include medical management, neurostimulation, and operative intervention, aim to minimize the symptoms caused by these conditions. The evidence base for many of these treatments in children is poor, and multiinstitutional prospective studies are needed. An innovative therapy on the horizon involves using neuronal stem cell transplantation to treat the underlying disorder by replacing the missing or damaged neurons in these diseases. Summary Although recent advances in basic and clinical neurogastroenterology have significantly improved our awareness and understanding of enteric neuropathies, the efficacy of current treatment approaches is limited. The development of novel therapies, including pharmacologic modulators of neurointestinal function, neurostimulation to enhance gut motility, and neuronal cell-based therapies, is essential to improve the long-term outcomes in children with these disorders.
  • Gastrointestinal Neuromuscular Pathology: Guidelines for Histological Techniques and Reporting on Behalf of the Gastro 2009 International Working Group

    Gastrointestinal Neuromuscular Pathology: Guidelines for Histological Techniques and Reporting on Behalf of the Gastro 2009 International Working Group

    Acta Neuropathol (2009) 118:271–301 DOI 10.1007/s00401-009-0527-y CONSENSUS PAPER Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group Charles H. Knowles Æ Roberto De Giorgio Æ Raj P. Kapur Æ Elisabeth Bruder Æ Gianrico Farrugia Æ Karel Geboes Æ Michael D. Gershon Æ John Hutson Æ Greger Lindberg Æ Joanne E. Martin Æ William A. Meier-Ruge Æ Peter J. Milla Æ Virpi V. Smith Æ Jean Marie Vandervinden Æ Be´la Veress Æ Thilo Wedel Received: 22 January 2009 / Revised: 19 March 2009 / Accepted: 22 March 2009 / Published online: 10 April 2009 Ó Springer-Verlag 2009 Abstract The term gastrointestinal neuromuscular dis- abnormalities have been demonstrated by a variety of ease describes a clinically heterogeneous group of methods in these conditions, standards for histopatholo- disorders of children and adults in which symptoms are gical reporting remain relatively neglected. Significant presumed or proven to arise as a result of neuromuscular, differences in methodologies and expertise continue to including interstitial cell of Cajal, dysfunction. Such dis- confound the reliable delineation of normality and speci- orders commonly have impaired motor activity, i.e. slowed ficity of particular pathological changes for disease. Such or obstructed transit with radiological evidence of transient issues require urgent clarification to standardize acquisition or persistent visceral dilatation. Whilst sensorimotor and handling of tissue specimens, interpretation of findings and make informed decisions on risk-benefit of full-thick- ness tissue biopsy of bowel or other diagnostic procedures. Electronic supplementary material The online version of this Such information will also allow increased certainty of article (doi:10.1007/s00401-009-0527-y) contains supplementary material, which is available to authorized users.
  • Pseudo-Obstruction, Enteric Dysmotility and Irritable Bowel Syndrome

    Best Practice & Research Clinical Gastroenterology 40-41 (2019) 101635 Contents lists available at ScienceDirect Best Practice & Research Clinical Gastroenterology journal homepage: https://ees.elsevier.com/ybega/default.asp Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome Greger Lindberg Karolinska Institutet, Department of Medicine, Huddinge and Karolinska University Hospital Huddinge, Patient Area Gastroenterology, Dermatology, and Rheumatology, SE-14186, Stockholm, Sweden article info abstract Article history: New diagnostic techniques have advanced our knowledge about the irritable bowel syndrome. The Received 25 March 2019 majority of patients that we believed to have a psychosomatic disorder have received other diagnoses Accepted 18 July 2019 explaining their symptoms. Endoscopy makes it possible to diagnose celiac disease before it leads to malnutrition and allows the detection of microscopic colitis as a cause of watery diarrhea. At the severe Keywords: end of the symptom spectrum enteric dysmotility marks the border at which IBS ceases to be a functional Irritable bowel syndrome disorder and becomes a genuine motility disorder. Joint hypermobility or Ehlers-Danlos syndrome is Enteric dysmotility present in a substantial proportion of patients with enteric dysmotility. Chronic intestinal pseudo- Chronic intestinal pseudo-obstruction Bile acid diarrhea obstruction is the end-stage of a large number of very rare disorders in which failed peristalsis is the Joint hypermobility common denominator. Nutritional
  • Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons

    Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons

    ORIGINAL RESEARCH published: 08 June 2017 doi: 10.3389/fphys.2017.00391 Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons Rachel M. McQuade 1, Vanesa Stojanovska 1, Elizabeth L. Donald 1, Ahmed A. Rahman 1, Dean G. Campelj 1, 2, 3, Raquel Abalo 4, Emma Rybalka 1, 2, 3, Joel C. Bornstein 5 and Kulmira Nurgali 1* 1 College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia, 2 Institute of Sport, Exercise and Active Living, Victoria University, Melbourne, VIC, Australia, 3 Australian Institute of Musculoskeletal Science, Western Health, Edited by: Melbourne, VIC, Australia, 4 Área de Farmacología y Nutrición y Unidad Asociada al Instituto de Química Médica y al Instituto L. Ashley Blackshaw, de Investigación en Ciencias de la Alimentación del Consejo Superior de Investigaciones Científicas, Grupo de Excelencia Queen Mary University of London, Investigadora URJC-Banco de Santander-Grupo Multidisciplinar de Investigación y Tratamiento del Dolor, Universidad Rey United Kingdom Juan Carlos, Alcorcón, Spain, 5 Department of Physiology, Melbourne University, Melbourne, VIC, Australia Reviewed by: Patrick Anthony Hughes, Gastrointestinal dysfunction is a common side-effect of chemotherapy leading to dose University of Adelaide, Australia Rainer Viktor Haberberger, reductions and treatment delays. These side-effects may persist up to 10 years Flinders University, Australia post-treatment. A topoisomerase I inhibitor, irinotecan (IRI), commonly used for the *Correspondence: treatment of colorectal cancer, is associated with severe acute and delayed-onset Kulmira Nurgali [email protected] diarrhea. The long-term effects of IRI may be due to damage to enteric neurons innervating the gastrointestinal tract and controlling its functions.